General Information of Drug Therapeutic Target (DTT) (ID: TTVOH3T)

DTT Name ISG15 messenger RNA (ISG15 mRNA)
Synonyms
hUCRP (mRNA); Ubiquitin-like protein ISG15 (mRNA); Ubiquitin cross-reactive protein (mRNA); UCRP (mRNA); Interferon-induced 17 kDa protein (mRNA); Interferon-induced 15 kDa protein (mRNA); IP17 (mRNA); G1P2 (mRNA)
Gene Name ISG15
DTT Type
Literature-reported target
[1]
BioChemical Class
mRNA target
UniProt ID
ISG15_HUMAN
TTD ID
T68498
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MGWDLTVKMLAGNEFQVSLSSSMSVSELKAQITQKIGVHAFQQRLAVHPSGVALQDRVPL
ASQGLGPGSTVLLVVDKCDEPLSILVRNNKGRSSTYEVRLTQTVAHLKQQVSGLEGVQDD
LFWLTFEGKPLEDQLPLGEYGLKPLSTVFMNLRLRGGGTEPGGRS
Function
ISGylation involves a cascade of enzymatic reactions involving E1, E2, and E3 enzymes which catalyze the conjugation of ISG15 to a lysine residue in the target protein. Its target proteins include IFIT1, MX1/MxA, PPM1B, UBE2L6, UBA7, CHMP5, CHMP2A, CHMP4B and CHMP6. Can also isgylate: EIF2AK2/PKR which results in its activation, DDX58/RIG-I which inhibits its function in antiviral signaling response, EIF4E2 which enhances its cap structure-binding activity and translation-inhibition activity, UBE2N and UBE2E1 which negatively regulates their activity, IRF3 which inhibits its ubiquitination and degradation and FLNB which prevents its ability to interact with the upstream activators of the JNK cascade therby inhibiting IFNA-induced JNK signaling. Exhibits antiviral activity towards both DNA and RNA viruses, including influenza A, HIV-1 and Ebola virus. Restricts HIV-1 and ebola virus via disruption of viral budding. Inhibits the ubiquitination of HIV-1 Gag and host TSG101 and disrupts their interaction, thereby preventing assembly and release of virions from infected cells. Inhibits Ebola virus budding mediated by the VP40 protein by disrupting ubiquitin ligase activity of NEDD4 and its ability to ubiquitinate VP40. ISGylates influenza A virus NS1 protein which causes a loss of function of the protein and the inhibition of virus replication. The secreted form of ISG15 can: induce natural killer cell proliferation, act as a chemotactic factor for neutrophils and act as a IFN-gamma-inducing cytokine playing an essential role in antimycobacterial immunity. The secreted form acts through the integrin ITGAL/ITGB2 receptor to initiate activation of SRC family tyrosine kinases including LYN, HCK and FGR which leads to secretion of IFNG and IL10; the interaction is mediated by ITGAL. Ubiquitin-like protein which plays a key role in the innate immune response to viral infection either via its conjugation to a target protein (ISGylation) or via its action as a free or unconjugated protein.
KEGG Pathway
RIG-I-like receptor signaling pathway (hsa04622 )
Human papillomavirus infection (hsa05165 )
Epstein-Barr virus infection (hsa05169 )
Coronavirus disease - COVID-19 (hsa05171 )
Reactome Pathway
NS1 Mediated Effects on Host Pathways (R-HSA-168276 )
DDX58/IFIH1-mediated induction of interferon-alpha/beta (R-HSA-168928 )
Termination of translesion DNA synthesis (R-HSA-5656169 )
Interferon alpha/beta signaling (R-HSA-909733 )
Negative regulators of DDX58/IFIH1 signaling (R-HSA-936440 )
SARS-CoV-2 activates/modulates innate and adaptive immune responses (R-HSA-9705671 )
ISG15 antiviral mechanism (R-HSA-1169408 )

References

1 Prognostic value of ISG15 mRNA level in drinkers with esophageal squamous cell cancers. Int J Clin Exp Pathol. 2015 Sep 1;8(9):10975-84.